سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

FDG PET/CT in Lung Cancer

Publish Year: 1397
Type: Conference paper
Language: English
View: 431
این Paper فقط به صورت چکیده توسط دبیرخانه ارسال شده است و فایل کامل قابل دریافت نیست. برای یافتن Papers دارای فایل کامل، از بخش [جستجوی مقالات فارسی] اقدام فرمایید.

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

Export:

Link to this Paper:

Document National Code:

LCPIMED03_003

Index date: 27 October 2018

FDG PET/CT in Lung Cancer abstract

A wide spectrum of advantages has been brought about by the development of positronemission tomography-computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) inmanagement of cancer patients, particularly lung malignancies.The prevalence of lung cancer in patients with solitary pulmonary nodules (SPN) varieswidely from 2-13% in screening studies to 46-82% in FDG PET/CT studies. The combination ofPET and CT in the hybrid imaging has showed an excellent performance in classifying SPN asbenign or malignant, where the sensitivity of CT and the specificity of PET, result in an overallsignificantly improved accuracy.FDG PET/CT has emerged as the most accurate non-invasive method for the evaluation ofmediastinal lymph node in the preoperative staging of non-small-cell lung cancer (NSCLC) with asensitivity, specificity and accuracy of 96%, 93% and 94%, respectively. In addition, the use ofFDG PET/CT in preoperative staging resulted in a different stage from that determined by standardmethods in about 50% of patients, with the stage lowered in 20% and raised in 41% of patients.Furthermore, FDG PET/CT possesses a significant value in the predicting of prognosis,assessment of response to therapy, and distinguishing recurrence, taking advantage of evaluation ofmetabolic activity of lesions rather than merely appearance.In conclusion, the incremental use of FDG PET/CT in assessment of lung cancer leads to anoverall reduction in treatment costs because significant numbers of patients will receive lessexpensive palliative therapies rather than more expensive radical treatments.

FDG PET/CT in Lung Cancer authors

Mohsen Beheshti

M.D, Associate Professor of Nuclear Medicine Paracelsus Medical University , Salzburg, Austria